These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24589944)

  • 21. Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients.
    Lu YP; Guo T; Wang BJ; Dong JH; Zhu JF; Liu Z; Lu MJ; Yang DL
    World J Gastroenterol; 2008 Jun; 14(22):3490-6. PubMed ID: 18567076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
    Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF
    Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.
    Tan YW; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    Braz J Infect Dis; 2012; 16(3):250-5. PubMed ID: 22729192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Cho YK; Cui XJ; Jeong SU; Song BC
    Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
    Seifer M; Patty A; Serra I; Li B; Standring DN
    Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients.
    Mese S; Arikan M; Cakiris A; Abaci N; Gumus E; Kursun O; Onel D; Ustek D; Kaymakoglu S; Badur S; Yenen OS; Bozkaya E
    J Gen Virol; 2013 Dec; 94(Pt 12):2729-2738. PubMed ID: 24045109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
    Guo X; Wu J; Wei F; Ouyang Y; Li Q; Liu K; Wang Y; Zhang Y; Chen D
    Int J Antimicrob Agents; 2018 Aug; 52(2):201-209. PubMed ID: 29654894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
    J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Ding C; Wong VW; Chow KC; Chan HY; Hui AY; Wong GL; Lo YM; Sung JJ; Chan HL
    Antivir Ther; 2006; 11(8):1041-9. PubMed ID: 17302374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of ALLGIO probe assays for detection of HBV resistance to adefovir in patients with chronic hepatitis B, Kerman, Iran.
    Afshar RM; Mollaie HR
    Asian Pac J Cancer Prev; 2012; 13(11):5463-7. PubMed ID: 23317201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.